Scholarlink

Background <p>Advanced epithelial ovarian cancer (EOC) is commonly diagnosed at late stages, and despite improvements with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS), prognosis remains poor. Body composition has emerged as an important determinant of treatment outcomes. Low muscle mass (LMM), particularly in obese patients with low muscle mass (OwLMM), may combine impaired functional reserve with adverse metabolic effects. However, its role in NACT outcomes in EOC remains unclear.</p> Methods <p>In this retrospective study, 52 overweight or obese women with FIGO stage III–IV EOC treated with platinum–taxane-based NACT and IDS between 2019 and 2022 were analyzed. Skeletal muscle mass was assessed on baseline computed tomography scans at the third lumbar vertebra (L3), and the lumbar skeletal muscle index (LSMI) was calculated. Patients were classified as LMM or high muscle mass (HMM) using the cohort median cut-off. Patients with both obesity and LMM were categorized as OwLMM. Treatment response was evaluated using RECIST v1.1 criteria.</p> Results <p>The median follow-up was 10.2 months (95% CI, 7.8–12.6). Median disease-free survival (DFS) from IDS was 19.3 months (95% CI, 8.5–30.1). OwLMM patients had lower objective response rates (46.7% vs. 62.2%, <i>p</i> = 0.02) and inferior disease control rates (80% vs. 100%, <i>p</i> = 0.03) compared with other groups. BMI or LMM alone showed no significant effect. Overall survival (OS) analysis was premature due to the short follow-up period.</p> Conclusion <p>Low muscle mass, especially when combined with obesity, was associated with reduced NACT response and inferior disease control in advanced EOC. As sarcopenic obesity represents a key component of frailty in older adults, our findings support muscle mass assessment as a clinically relevant biomarker that may improve risk stratification and guide individualized therapy in geriatric oncology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Low muscle mass predicts poor response to neoadjuvant chemotherapy in advanced ovarian cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月16日

查看全文
  • Derya Demirtaş Esmer,
  • Emre Hafızoğlu,
  • Murat Bardakçı,
  • Erdem Özkan,
  • Serhat Sekmek,
  • Doğan Bayram,
  • İrfan Karahan,
  • Efnan Algın,
  • Öznur Bal

摘要

Background

Advanced epithelial ovarian cancer (EOC) is commonly diagnosed at late stages, and despite improvements with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS), prognosis remains poor. Body composition has emerged as an important determinant of treatment outcomes. Low muscle mass (LMM), particularly in obese patients with low muscle mass (OwLMM), may combine impaired functional reserve with adverse metabolic effects. However, its role in NACT outcomes in EOC remains unclear.

Methods

In this retrospective study, 52 overweight or obese women with FIGO stage III–IV EOC treated with platinum–taxane-based NACT and IDS between 2019 and 2022 were analyzed. Skeletal muscle mass was assessed on baseline computed tomography scans at the third lumbar vertebra (L3), and the lumbar skeletal muscle index (LSMI) was calculated. Patients were classified as LMM or high muscle mass (HMM) using the cohort median cut-off. Patients with both obesity and LMM were categorized as OwLMM. Treatment response was evaluated using RECIST v1.1 criteria.

Results

The median follow-up was 10.2 months (95% CI, 7.8–12.6). Median disease-free survival (DFS) from IDS was 19.3 months (95% CI, 8.5–30.1). OwLMM patients had lower objective response rates (46.7% vs. 62.2%, p = 0.02) and inferior disease control rates (80% vs. 100%, p = 0.03) compared with other groups. BMI or LMM alone showed no significant effect. Overall survival (OS) analysis was premature due to the short follow-up period.

Conclusion

Low muscle mass, especially when combined with obesity, was associated with reduced NACT response and inferior disease control in advanced EOC. As sarcopenic obesity represents a key component of frailty in older adults, our findings support muscle mass assessment as a clinically relevant biomarker that may improve risk stratification and guide individualized therapy in geriatric oncology.